AUROBINDO PHARMA (AUROPHARMA.NS) Financials
AUROPHARMA.NS Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | ? | ? |
| 2023-09-30 | 439.2 billion | 157.3 billion |
| 2023-06-30 | ? | ? |
| 2023-03-31 | 398.9 billion | 130.4 billion |
AUROPHARMA.NS Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 8.5 billion | ? |
| 2023-09-30 | 47.2 million | ? |
| 2023-06-30 | 6.5 billion | ? |
| 2023-03-31 | -57.5 million | -57.5 million |
AUROPHARMA.NS Net Income
| Date | Net Income |
|---|---|
| 2023-12-31 | 9.4 billion |
| 2023-09-30 | 7.6 billion |
| 2023-06-30 | 5.7 billion |
| 2023-03-31 | 5.1 billion |
AUROPHARMA.NS Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | - | - | - |
| 2023-09-30 | 74.4 billion | 20.3 billion | 4.0 billion |
| 2023-06-30 | 62.3 billion | - | - |
| 2023-03-31 | 65.3 billion | 9.4 billion | 4.2 billion |
AUROPHARMA.NS Shares Outstanding
AUROPHARMA.NS Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | - | 4.0 billion | - | - |
| 2023-09-30 | 15.0 billion | 3.0 billion | 9.5 billion | - |
| 2023-06-30 | - | 3.9 billion | 9.5 billion | - |
| 2023-03-31 | 27.2 billion | 4.1 billion | 8.5 billion | - |
AUROPHARMA.NS Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 72.7 billion | 31.5 billion |
| 2023-09-30 | 71.5 billion | 32.4 billion |
| 2023-06-30 | 67.9 billion | 31.5 billion |
| 2023-03-31 | 63.8 billion | 29.3 billion |
AUROPHARMA.NS
Price: ₹1,229.85
Dividend Yield: 0.00%
Forward Dividend Yield: 0.24%
Payout Ratio: 6.36%
Dividend Per Share: 3.00 INR
Earnings Per Share: 47.26 INR
P/E Ratio: 25.35
Exchange: NSI
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Market Capitalization: 653.5 billion
Average Dividend Frequency: 2
Years Paying Dividends: 24
DGR3: 13.07%
DGR5: 24.07%
DGR10: 18.60%
DGR20: 30.00%